{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:34:23Z","timestamp":1791362063687,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018689","name":"SCReN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Asuntos Econ\u00f3micos y Transformaci\u00f3n Digital, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01372"],"award-info":[{"award-number":["PI17\/01372"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cmi.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:25:36Z","timestamp":1729369536000},"page":"211-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of extended infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Julia","family":"Laporte-Amargos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Carmona-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Puerta-Alcalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rigo-Bonnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ulldemolins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Torrent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e0lia","family":"Pallar\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Teb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fe","family":"Tubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Padull\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.10.006_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.10.006_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2024.10.006_bib3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.006_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/QCO.0b013e32835915c2","article-title":"Infusional \u03b2-lactam antibiotics in febrile neutropenia: has the time come?","volume":"25","author":"Abbott","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.006_bib5","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1128\/AAC.00389-15","article-title":"Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies","volume":"59","author":"Sime","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jiac.2019.02.014","article-title":"Evaluation of pharmacokinetic\/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia","volume":"25","author":"Weber","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib7","article-title":"Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients","volume":"53","author":"Lafaurie","year":"2023","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.cmi.2024.10.006_bib8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1177\/10781552231213883","article-title":"Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies","volume":"30","author":"Lodl","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cmi.2024.10.006_bib9","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.49.8.3550-3553.2005","article-title":"Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure","volume":"49","author":"Pea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib10","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib11","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/jac\/dkaa275","article-title":"A\u00a0meropenem pharmacokinetics model in patients with haematological malignancies","volume":"75","author":"Contejean","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00311-17","article-title":"Using population pharmacokinetic modeling and Monte Carlo simulations to determine whether standard doses of piperacillin in piperacillin-tazobactam regimens are adequate for the management of febrile neutropenia","volume":"61","author":"Sime","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ijantimicag.2017.04.008","article-title":"Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens","volume":"50","author":"Rhodes","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.10.006_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jphs.2014.12.003","article-title":"Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia","volume":"127","author":"Jaruratanasirikul","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.cmi.2024.10.006_bib15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/phar.2844","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2024.10.006_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2024.10.006_bib17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2024.10.006_bib18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciy258","article-title":"Extended vs bolus infusion of broad-spectrum \u03b2-lactams for febrile neutropenia: an unblinded, randomized trial","volume":"67","author":"Ram","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.006_bib19","first-page":"190","article-title":"Prolonged vs short-term infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia: a systematic review and meta-analysis","volume":"87","author":"Laporte-Amargos","year":"2023","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2024.10.006_bib20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/antibiotics12061024","article-title":"Effectiveness of extended or continuous vs. bolus infusion of broad-spectrum beta-lactam antibiotics for febrile neutropenia: a systematic review and meta-analysis","volume":"12","author":"Ishikawa","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.10.006_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s13063-020-04323-0","article-title":"Efficacy of extended infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)","volume":"21","author":"Laporte-Amargos","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.cmi.2024.10.006_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2017.03.009","article-title":"Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of \u03b2-lactam antibiotic concentration in human plasma","volume":"468","author":"Rigo-Bonnin","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cmi.2024.10.006_bib23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.10.006_bib25","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dku150","article-title":"Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study","volume":"69","author":"Feh\u00e9r","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.10.006_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155216687151","article-title":"Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia","volume":"24","author":"Wrenn","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.cmi.2024.10.006_bib27","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2024.10.006_bib28","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/phar.2728","article-title":"Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia","volume":"42","author":"Crawford","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2024.10.006_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/IPC.0000000000000600","article-title":"Extended versus intermittent infusions of cefepime for the treatment of febrile neutropenia","volume":"26","author":"Przybylski","year":"2018","journal-title":"Infect Dis Clin Pract"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:53:47Z","timestamp":1738450427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1198743X24004889"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.10.006","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of extended infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}